Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;182(5):1309-1310.
doi: 10.1111/bjd.18631. Epub 2019 Dec 13.

Autoimmune disease development before and after cutaneous lupus erythematosus diagnosis

K Y Shi  1 , E Kunzler  1 , L S Hynan  2 , B F Chong  1
Affiliations

Autoimmune disease development before and after cutaneous lupus erythematosus diagnosis

K Y Shi et al. Br J Dermatol. 2020 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: B.F. Chong is an investigator for Daavlin Corporation, Biogen Incorporated, and Pfizer Incorporated. He has received honoraria from Viela Bio as a consultant. The other authors have no conflicts of interest.

Figures

Fig. 1.
Fig. 1.
Timing and accumulation of new-onset autoimmune disease after CLE diagnosis. A) Timing distribution of new-onset autoimmune diagnoses after CLE diagnosis showed that SLE did not progress differently than other autoimmune diseases. B) Survival analysis of new-onset autoimmune disease development in CLE patients grouped by ANA status (ANA positive: ≥1:160 titer, at any time during follow-up). CLE patients with positive ANA showed greater risk of developing new-onset autoimmune diseases over time than those with negative ANA. p-value was determined by Log Rank test. Abbreviations: ANA, anti-nuclear antibody, CLE, cutaneous lupus erythematosus
See this image and copyright information in PMC

References

    1. McDonagh JE, Isenberg DA. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis. 2000;59(3):230–232. - PMC - PubMed
    1. Chambers SA, Charman SC, Rahman A, Isenberg DA. Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Ann Rheum Dis. 2007;66(9):1173–1177. - PMC - PubMed
    1. Kunzler E, Hynan LS, Chong BF. Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus. JAMA Dermatol. 2018;154(6):712–716. - PMC - PubMed
    1. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and rheumatism. 2012;64(8):2677–2686. - PMC - PubMed
    1. Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11(10):754–765. - PubMed

Publication types

MeSH terms